Aethlon Medical, Inc. (AEMD)

NASDAQ: AEMD · IEX Real-Time Price · USD
0.429
-0.007 (-1.61%)
Nov 25, 2022 4:00 PM EDT - Market closed
-1.61%
Market Cap 10.00M
Revenue (ttm) 30,233
Net Income (ttm) -13.02M
Shares Out 20.74M
EPS (ttm) -0.61
PE Ratio n/a
Forward PE 0.20
Dividend n/a
Ex-Dividend Date n/a
Volume 46,617
Open 0.44
Previous Close 0.436
Day's Range 0.424 - 0.443
52-Week Range 0.39 - 2.73
Beta 0.90
Analysts Buy
Price Target 7.14 (+1,564.7%)
Earnings Date Nov 14, 2022

About AEMD

Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for stud... [Read more]

Industry Health Care Equipment & Supplies
CEO Timothy Rodell
Employees 14
Stock Exchange NASDAQ
Ticker Symbol AEMD
Full Company Profile

Financial Performance

In 2021, AEMD's revenue was $294,165, a decrease of -55.37% compared to the previous year's $659,104. Losses were -$10.42 million, 32.1% more than in 2020.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for AEMD stock is "Buy." The 12-month stock price forecast is 7.14, which is an increase of 1,564.72% from the latest price.

Price Target
$7.14
(1,564.72% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Aethlon Medical Announces Second Quarter Financial Results and Provides Corporate Update

SAN DIEGO , Nov. 14, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious ...

1 week ago - PRNewsWire

Aethlon Medical to Release Second Quarter Financial Results and Host Conference Call on November 14, 2022

SAN DIEGO , Nov. 2, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical therapeutics to treat cancer and life-threatening infectious disease, today announced that it ...

3 weeks ago - PRNewsWire

Aethlon Medical to Present at Two Investor Conferences in September

SAN DIEGO , Sept. 6, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life-threatening infectious ...

2 months ago - PRNewsWire

Aethlon Medical Announces First Quarter Financial Results and Provides Corporate Update

SAN DIEGO , Aug. 9, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious d...

3 months ago - PRNewsWire

Aethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 9, 2022

SAN DIEGO , Aug. 3, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical therapeutics to treat cancer and life-threatening infectious disease, today announced that it ...

3 months ago - PRNewsWire

Aethlon Medical Announces Publication of Peer-Reviewed Journal Article Describing Hemopurifier Resin Binding of Seven...

SAN DIEGO , July 28, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious ...

3 months ago - PRNewsWire

Aethlon Medical Announces U.S. FDA Approval of Hemopurifier COVID-19 Study Protocol Amendment

Approval eliminates the requirement for previous dialysis treatment, potentially enabling accelerated enrollment in the ongoing clinical study SAN DIEGO , July 11, 2022 /PRNewswire/ -- Aethlon Medical, ...

4 months ago - PRNewsWire

Aethlon Medical Announces Fiscal Year End Financial Results and Provides Corporate Update

SAN DIEGO , June 28, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening infectious di...

4 months ago - PRNewsWire

Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 28, 2022

SAN DIEGO , June 21, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced that it w...

5 months ago - PRNewsWire

Aethlon Medical to Present at the H.C. Wainwright Global Investment Conference

SAN DIEGO, May 17, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, today...

6 months ago - PRNewsWire

Aethlon Medical Publishes In Vitro Studies Demonstrating Hemopurifier Resin Binding of Seven Clinically Relevant COVI...

Viral capture efficiency ranged from 53% to 89% for the seven COVID-19 variants tested SAN DIEGO, May 2, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused o...

6 months ago - PRNewsWire

Aethlon Medical, Inc. Appoints Angela Rossetti to Board of Directors

SAN DIEGO, March 28, 2022 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon") (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening d...

7 months ago - PRNewsWire

Aethlon Medical Announces Third Quarter Financial Results and Provides Corporate Update

SAN DIEGO, Feb. 14, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious diseases, today reported financial ...

9 months ago - PRNewsWire

Aethlon Medical to Release Third Quarter Financial Results and Host Conference Call on February 14, 2022

SAN DIEGO, Jan. 31, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced that it wi...

9 months ago - PRNewsWire

Alzamend Neuro Announces Positive Topline Data from Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Deme...

TAMPA, Fla.--(BUSINESS WIRE)---- $AEMD #505B2--Alzamend Neuro Announces Positive Topline Data from Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer's

11 months ago - Business Wire

Aethlon Medical to Release Second Quarter Financial Results and Host Conference Call on November 9, 2021

SAN DIEGO, Nov. 2, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced that it wil...

1 year ago - PRNewsWire

Aethlon Medical Announces Peer-Reviewed Publication of Two Case Studies of Critically Ill COVID-19 Patients Treated w...

SAN DIEGO, Oct. 12, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced the public...

1 year ago - PRNewsWire

Aethlon Medical Announces Contracting with PPD to Advance Hemopurifier Clinical Programs

SAN DIEGO, Sept. 30,  2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced that it ...

1 year ago - PRNewsWire

8 Things to Know About Aethlon Medical as Investors Send AEMD Stock Soaring Today

Aethlon Medical (AEMD) stock is rising higher on Wednesday due to heavy trading despite a lack of news from the company. The post 8 Things to Know About Aethlon Medical as Investors Send AEMD Stock Soar...

1 year ago - InvestorPlace

Aethlon Medical to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

SAN DIEGO, Sept. 7, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, toda...

1 year ago - PRNewsWire

Aethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 9, 2021

SAN DIEGO, July 29, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial r...

1 year ago - PRNewsWire

Aethlon Medical to Release Fourth Quarter Financial Results and Host Conference Call on June 24, 2021

SAN DIEGO, June 21, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial r...

1 year ago - PRNewsWire

Why Aethlon Medical's Stock Is Plunging Today

After surging 400% yesterday, Aethlon Medical, Inc. (NASDAQ: AEMD) shares are trading lower after the company announced a 1.38-million share registered direct offering priced at $9 per share. The gross ...

1 year ago - Benzinga

Aethlon Medical Announces $12.425 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SAN DIEGO, June 10, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq:AEMD), a medical device technology company focused on unmet needs in global health, today announced that it has entered into a defi...

1 year ago - PRNewsWire

Aethlon Medical stock explodes 465% on heavy volume as new report about COVID-19 treatment inspires social-media disc...

Shares of Aethlon Medical exploded as much as 465% to a two-year high on Wednesday despite not releasing any news since last week, when one of its devices showed positive results in two COVID-19 patient...

1 year ago - Business Insider